Pneumocystis carinii pneumonia (PCP) is the most frequent opportunistic infection in patients with AIDS, occurring in 80% and recurring in 50% of patients within 12 months of the first episode. Prophylaxis for PCP is recommended if the CD4 + cell count is <200x 10 6 /1or 20% of the total lymphocyte count, or after an episode of PCP. The most effective prophylactic agent currently is trimethoprimsulphamethoxazole and should be the drug of choice but alternatives such as aerosol pentamidine are being increasingly used for patients who cannot tolerate this combination or other oral preparations. If aerosol pentamidine is used and administered via a Respigard II Marquest nebulizer, the dosage should be higher than the currently recommended monthly dosage of 300mg.
The use of prophylaxis regimens to prevent first or subsequent episodes of pneumocystis carinii pneumonia (PCP) has been a major advance in the management of patients with moderate or severe immunosuppression caused by the human immunodeficiency virus (HIV) infection. Since the acquired immunodeficiency syndrome (AIDS) epidemic began in the early 1980s, clinicians recognized that PCP caused considerable morbidity and mortality, and some patients had multiple episodes. Oral cotrimoxazole had been shown to be highly effective in preventing PCP in paediatric cancer patients'. In a randomized controlled study amongst patients with Kaposi's sarcoma and no prior history of PCP, co-trimoxazole was effective in preventing PCP during a mean of 24 months' follow-ups, Fansidar and dapsone with or without pyrimethamine has also provided effective prophylaxis 3 -S , although neither has been compared with co-trimoxazole in a large prospective study. While all three options are relatively cheap adverse reactions occur in a significant proportion of HIV infected patientss-", Against this background aerosolized pentamidine has been developed both as an alternative prophylactic regimen directed to the lungs with few systemic adverse effects and as active treatment for mild infectionsv'P. A trial of aerosol pentamidine prophylaxis using the Respigard nebulizer in San Francisco"! showed that in patients with prior PCP, aerosolized pentamidine 300 mg every 4 weeks resulted in a one-year estimated relapse rate of 22% compared with over 40% relapse at 30 mg pentamidine every 2 weeks. Aerosolized pentamidine was extremely well-tolerated. As a result of this study the Food and Drug Administration in the USA approved the use of prophylactic aerosol pentamidine in June 1989 and since then this has become widely used. It was appealing to clinicians initially to have a regimen that was effective and well-tolerated although the costs of drug acquisition and drug delivery for treating patients with aerosolized pentamidine have been considerable. The results of this trial have however posed 4 major questions for clinicians caring for patients infected with the HIV: 1. Was the Respigard nebulizer the optimal delivery device for depositing an adequate amount of pentamidine to the alveoli; 2. Was the regimen of 300 mg every 4 weeks the optimal dose; 3. Does the high cost of aerosol pentamidine justify its use as a first choice prophylaxis, and 4. Was the prophylaxis failure rate acceptable compared to what could be achieved with oral co-trimoxazole, dapsone/pyrimethamine or fansidar?
Three other aerosol delivery devices have been assessed for delivering pentamidine to the lungs. The Fisoneb ultrasonic nebulizer was used in a recent triaP2 comparing the efficacy and safety of 3 dosing regimens of 5 mg, 60 mg, or 120 mg of aerosol pentamidine given every 2 weeks in a double-blind fashion after a loading dose for patients who had a history of PCP. The investigators made a change in their protocol when the results of the San Francisco triall! became known; all patients receiving the 5 mg dose were randomiz.ai to higher doses. Unfortunately there was no control arm after the discontinuation of the 5 mg dose, and therefore the results can only be compared with those in historical control subjects. The estimated cumulative one-year relapse rate was 12% for the 60 mg group and 7% for the 120mg group. A recent placebo-controlled study in Canada also showed the efficacy of aerosol pentamidine delivered by the Pisoneb's. The System 22 Mizer and another modified system using a System 22 antibiotic tee-tube and acorn nebulizing chamber with an Optimist Master particle acting as a baffle are widely used in UK although not tested in any controlled trials 14-18.
Performance characteristics of all these 4 nebulizers differ in terms of the profile of particle sizes generated and the efficiency of drug delivery. In particular, the Fisoneb produces the aerosol on demand in contrast to the continuous drug delivery provided by the other 3 systems. Because of these differences between the delivery systems, the delivery of drug to the alveoli by the 4 nebulizers is dramatically different for a fixed drug dose. Thus, the toxicity and efficacy of a given dose of pentamidine administered by the Fisoneb and the Respigard used recently in both studies ll,12 need to be compared separately.
Is there any reason why clinicians should consider the use of one delivery system over the other? Toxicities associated with all 4 delivery systems are mild and comparable although the aerosol droplets generated by System 22 Mizer are larger, resulting in increased central deposition and more frequent local adverse effects. The modified acorn nebulizer with the Optimist Master particle sizer generate similar aerosol size particles as the Respigard, is re-usable and thus cheaper. Thus there is no demonstrable reason to choose one device over the other in terms of patient safety. The Fisoneb may have some potential advantages; it is hand-held, self-contained, and does not require compressed gas or oxygen and is therefore more portable and better suited for home use. In addition, the ultrasonic nebulizer uses 120 mg of pentamidine twice monthly instead of 300 mg once monthly or more, thus potentially decreasing drug costs. To prove which of these systems is superi.or to anoth~r would require a large and costly tnal~n~the~ifferences are likely to be small. Such a trial is unlikely to be performed because of the high cost. A one-year estimated relapse rate of 22% on monthly 3oo.mg of aerosol pentamidine shown by th~San Fran~lsco triall! indicates that this regimen IS not optimal. There is an urgent need for further prospective randomized trials to determine whether higher doses using the Respigard delivery device provide more efficacy. A recent open-labelled studyl'' showed no relapses after a mean duration of follow-up of 14.9 months on a weekly 600 mg dosing regimen and serial pulmonary function tests showed no significant differences during the study. Any future trials should therefore include such a dosing regimen. A higher dosing regimen using the Fisoneb delivery system needs further evaluation.
Interim data'? from a Phase III comparison study (Acre 021)of the toxicity and efficacy of zidovudine (1~mg every 4 h) combined with either (1) cotrimoxazole one double-strength daily, or (2) aerosolized pentamidine 300 mg every 4 weeks using the Marquest Respigard II nebulizer for preventing recurrence of PCP were recently reviewed by an independent Data and Safety Monitoring Board. While the study showed both regimens to be effective, the results showed the superior efficacy of co-trimoxazole in preventing or delaying recurrent PCP in participants who have had an initial episode of HIV-related PCP.
Oral co-trimoxazole is no doubt cheaper and is cost-effective'? and should be the drug of choice initially for HIV-infected patients with no previous adverse reactions to the drug and who are at increased risk of developing PCp21. An increasing number of uncontrolled trials are now reporting exceedingly low relapse rates for patients on intermittent co-trimoxazo1e22,23. Although encouraging, they cannot be considered as showing a definitive advantage for co-trimoxazole. Other oral preparations such as intermittent dapsone', weekly pyrimethamine-sulfadoxine 24 and 566C80 25 (an investigational hydroxynapthoquinone) warrant consideration for large prophylaxis trials. These alternatives could provide better protection than aerosol pentamidine, reasonable tolerability, and some protection against toxoplasmosis as well.
Aerosol pentamidine has been an important addition in our management approach for prevention of PCP in patients infected with HIV and is unquestionably a good alternative for those who are intolerant of an oral regimen. The side effects are few; it should not be administered to a patient who has had hypoglycaemia, pancreatitis, arrhythmia Or severe hypotension associated with any form of pentamidine. This regimen should be administered to patients who had previous PCP with caution as they are more likely to bronchoconstrict, which may be prevented by inhalational beta-2 agonists or disodlumcrornoglycate". Clinicians need to be aware that a dosing regimen higher than the Current recommended monthly 300 mg should be used in view of the unacceptably high relapse rate shown by the San Francisco trial and other trials using similar low doses and frequency regimen. Ong. 
